Standard Chartered PLC Share Price Today: Stock Slips Despite Fresh Buyback and Citi Hire

March 27, 2026
Standard Chartered PLC Share Price Today: Stock Slips Despite Fresh Buyback and Citi Hire

LONDON, March 27, 2026, 11:02 GMT

Standard Chartered shares fell about 1.5% in London on Friday to 1,530.75 pence by 1102 GMT, extending a volatile week after a 3.95% slide in the previous session. The stock is down 15.6% this year and remains well below the 19.24-pound high reached on Feb. 3. 1

The latest move lands at an awkward point for the bank. Investors are weighing whether capital returns and an expanded investment-banking push can offset concern over Middle East exposure and the management churn that followed February’s abrupt CFO exit. J.P. Morgan analysts said earlier this month that Standard Chartered and HSBC were the most exposed among European lenders to the conflict, with StanChart’s Middle East exposure estimated at about 8% of revenue and 12% of pretax profit. 2

A Reuters brief on Friday, citing a Hong Kong filing, said Standard Chartered bought back 942,750 shares on March 26 for 14.8 million pounds on other exchanges. The pace has been steady: separate Reuters briefs showed purchases of 945,698 shares on March 25 and 952,044 on March 24. 1

The bank is also adding senior dealmaking staff. Standard Chartered said Jan Metzger, Citigroup’s co-head of Asia investment banking, will join in July as global head of coverage banking, based in Hong Kong and reporting to Roberto Hoornweg, while Reuters reported he is leaving Citi after eight years in the regional role. 3

Hoornweg said the bank’s success depends on “a global client-first mindset, relentless execution and assembling the best talent,” adding that Metzger would help “accelerate the momentum” in its franchise. The hire fits Bill Winters’ broader push toward fee-generating business lines and advisory work. 4

That strategy is already central to the Standard Chartered story. When the lender reported full-year results in February, it posted pretax profit of $6.96 billion, up 16% but short of the $7.2 billion analyst consensus, and announced a $1.5 billion buyback plus a 65% higher full-year dividend. Winters said then that “the board has also been clear they would like me to see through this strategy”, while investor relations head Manus Costello said China-Southeast Asia business volumes rose 20% last year and China-Middle East and China-Africa flows were up 18% and 25%. 5

There is a clear upside case, but also a risk one. Morningstar analyst Kathy Chan said “increased economic uncertainty could imply some additional risks related to the Groups’ trade finance and credit costs”, though Hargreaves Lansdown’s Matt Britzman said disruption can also lift demand for foreign exchange and cash-management services; Reuters reported JPMorgan and Citi are also expanding in the Gulf, underscoring the competitive pull of that corridor. 2

The next scheduled test is first-quarter results on April 30. Investors will be looking for signs that the buyback and investment-banking buildout are translating into steadier earnings, and that geopolitical strain is not yet feeding into higher credit costs or weaker client activity. 6

Stock Market Today

  • Stakebuilding in Everyman Media and Delays for Switch Metals Mineral Estimate on AIM
    March 27, 2026, 7:21 AM EDT. Omniplex has taken a 5.35% stake in Everyman Media Group, boosting its share price by 13.7% to 29p. ImmuPharma shares rose 10.3% after positive patent news and ongoing interest in its autoimmune disease program. Rockrose Energy increased its stake in Deltic Energy, lifting shares 7.14%, while Hargreaves Services raised its tender offer price and spending limit, pushing shares up 7.14%. In contrast, Switch Metals shares plunged 24.1% after announcing delays to its mineral resource estimate for the Issia project. Parkmead Group's shares fell 8.33%, despite increased cash reserves and future asset sale potential. Seeing Machines faced a 4.84% drop amid revenue declines but expects profitability later this year. Coiled Therapeutics transitioned to AIM, raising funds amid initial share price volatility.